A Study of LY3471851 in Participants With Eczema

Nektar Therapeutics

Status and phase: Completed; Phase 1

Conditions: Dermatitis, Atopic

Treatments: Drug: LY3471851; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04081350

17240

J1P-MC-KFAD (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Enrollment: 48 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months
• Have active AD according to study specific criteria
• Be willing and able to undergo skin biopsies

Exclusion criteria

• Have received certain topical medications for AD within 14 days prior to baseline
• Have received certain systemic medications for AD within 4 weeks prior to baseline
• Have received LY3471851 previously

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

48 participants in 4 patient groups, including a placebo group

10 µg/kg LY3471851

Active Comparator group

Description:

Participants received subcutaneous (SC) injection of 10 microgram per kilogram (μg/kg) LY3471851 every 2 weeks for a treatment period of 12 weeks.

Treatment:

Drug: LY3471851

12 µg/kg LY3471851

Active Comparator group

Description:

Participants received subcutaneous injection of 12 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.

Treatment:

Drug: LY3471851

24 µg/kg LY3471851

Active Comparator group

Description:

Participants received subcutaneous injection of 24 μg/kg LY3471851 every 2 weeks for a treatment period of 12 weeks.

Treatment:

Drug: LY3471851

Placebo

Placebo Comparator group

Description:

Participants received subcutaneous injection of placebo every 2 weeks for a treatment period of 12 weeks.

Treatment:

Drug: Placebo